Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Rami G. Azrak"'
Autor:
Youcef M. Rustum, Arup Bhattacharya, Farukh A. Durrani, Rami G. Azrak, Shousong Cao, Karoly Toth
Publikováno v:
Cancer Letters. 311:219-229
The goal of this study is to determine whether treatment with methylselenocysteine (MSC) results in differential uptake of irinotecan and its active metabolite (SN-38) between tumors of head and neck squamous cell carcinomas and normal tissue. The in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3332d86165d1d82eacad8d5188856cc
https://doi.org/10.1016/j.canlet.2011.07.023
https://doi.org/10.1016/j.canlet.2011.07.023
Autor:
Fengzhi Li, Gregory E. Wilding, Satish Sharma, Shaozeng Zhang, Masoud H. Manjili, Ali Ghadersohi, Rami G. Azrak
Publikováno v:
The Prostate. 71:1178-1188
Background Reduced expression of prostate-derived Ets transcription factor (PDEF) leads to morphologic change as well as increased migration and invasiveness of prostate cancer cells. However, the clinical relevance of PDEF expression and its relatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3f6964e900c26affc5076030138245ae
https://doi.org/10.1002/pros.21333
https://doi.org/10.1002/pros.21333
Autor:
Rami G. Azrak, Qiaoli Zhang
Publikováno v:
Journal of Nanjing Medical University. 23:111-116
Objective The role of methylseleninic acid (MSeA), a selenium compound, has been documented in cancer chemoprevention. However, the therapeutic effect of MSeA in combination with paclitaxel, a chemotherapeutic agent used to treat ovarian cancer, is u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7c80d444e16bcaa4f6c9f88b2b20e985
https://doi.org/10.1016/s1007-4376(09)60037-x
https://doi.org/10.1016/s1007-4376(09)60037-x
Autor:
Youcef M. Rustum, Farukh A. Durrani, Gerald F. Combs, Joshua Prey, Lakshmi Pendyala, Patrick F. Smith, Rami G. Azrak, Marwan Fakih, Shousong Cao
Publikováno v:
Biochemical Pharmacology. 73:1280-1287
This study was designed to understand the basis for the efficacy of methylselenocysteine (MSC) in increasing the therapeutic index of irinotecan against human tumor xenografts. Nude mice bearing human FaDu and A253 tumors were treated orally with dif
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fdb436b0293e93a5c63a541fd1065df6
https://doi.org/10.1016/j.bcp.2006.12.020
https://doi.org/10.1016/j.bcp.2006.12.020
Autor:
Fengzhi Li, Harry K. Slocum, Cheryl Frank, Xiang Ling, Youcef M. Rustum, Barbara A. Foster, Rami G. Azrak
Publikováno v:
Molecular Cancer Therapeutics. 5:2540-2548
The study was designed to evaluate the combination treatment of methylselenocysteine (MSeC) and docetaxel and to delineate the underlying mechanism associated with observed in vitro synergy between MSeC and docetaxel in prostate cancer cells. Cells w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bf4db6d7af477a88828fb9c65c87e9d
https://doi.org/10.1158/1535-7163.mct-05-0546
https://doi.org/10.1158/1535-7163.mct-05-0546
Autor:
Ming-Biao Yin, Gunnar Hapke, Rami G. Azrak, Karoly Toth, Arup Bhattacharya, Cheryl Frank, Li Zr, Farukh A. Durrani, Shousong Cao, Y. M. Rustum
Publikováno v:
Oncogene. 25:2509-2519
Until recently, the use of Se-methylselenocysteine (MSC) as selective modulator of the antitumor activity and selectivity of anticancer drugs including irinotecan, a topoisomerase I poison, had not been evaluated. Therapeutic synergy between MSC and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9f6fc03c7b30148fc8a34682439de59
https://doi.org/10.1038/sj.onc.1209073
https://doi.org/10.1038/sj.onc.1209073
Autor:
Lakshmi Pendyala, Vladimir Badmaev, David Lawrence, Joshua Prey, Marwan Fakih, Mary E. Reid, Patrick F. Smith, Rami G. Azrak, Youcef M. Rustum, Patrick J. Creaven
Publikováno v:
Clinical Cancer Research. 12:1237-1244
PURPOSE: We conducted a phase I study to determine the maximum tolerated dose (MTD) of irinotecan with fixed, nontoxic high dose of selenomethionine. EXPERIMENTAL DESIGN: Selenomethionine was given orally as a single daily dose containing 2,200 mug o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c63fd538f61ba12b71dfcfdff7eefa90
https://doi.org/10.1158/1078-0432.ccr-05-2004
https://doi.org/10.1158/1078-0432.ccr-05-2004
Autor:
Rami G. Azrak, Youcef M. Rustum, Farukh A. Durrani, Zhan-Rong Li, Ming-Biao Yin, Cheryl Frank, Shousong Cao
Publikováno v:
Molecular Pharmacology. 66:153-160
Methylselenocysteine (MSC) is an organic selenium compound in preventative clinical trials involving prostate, lung, and colon carcinoma. We found that methioninase-activated MSC potentiates 7-ethyl-10-hydroxycamptothecin (SN-38)-induced cell lethali
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d86aaaef2eea80cf6ec460858ca22d0
https://doi.org/10.1124/mol.66.1.153
https://doi.org/10.1124/mol.66.1.153
Autor:
Ming-Biao Yin, Carol Wrzosek, Rami G. Azrak, Cheryl Frank, Gunnar Hapke, Youcef M. Rustum, Jiaxi Wu
Publikováno v:
Biochemical and Biophysical Research Communications. 295:435-444
A novel karenitecin, BNP1350, is a topoisomerase I-targeting anticancer agent with significant antitumor activity in vitro and in vivo. A BNP1350-resistant human head and neck carcinoma A253 cell line, denoted A253/BNPR, was developed. The A253/BNPR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6c92d0efd8105343339180ec5ce2d67
https://doi.org/10.1016/s0006-291x(02)00683-6
https://doi.org/10.1016/s0006-291x(02)00683-6
Publikováno v:
Oncogene. 20:5249-5257
Promotion of apoptosis may potentiate the sensitivity of tumor cells to chemotherapeutic agents, thus improving the efficacy of cancer treatment. The transfection of the proapoptotic bax gene, which results in the overexpression of bax protein, augme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e214e8394dfe423d209769e126773ccf
https://doi.org/10.1038/sj.onc.1204686
https://doi.org/10.1038/sj.onc.1204686